BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220829
DTEND;VALUE=DATE:20220902
DTSTAMP:20260516T025924
CREATED:20220527T124300Z
LAST-MODIFIED:20220527T124300Z
UID:34298-1661731200-1662076799@www.pharmajournalist.com
SUMMARY:6th IPF Summit
DESCRIPTION:With two approved therapeutics and the field working to develop the next generation of IPF drugs\, the opportunity to become the undisputed\, most effective\, and disease-modifying agent on the market has never been greater. \nFrom repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development. \nWhat’s new and unmissable for 2022: \n\n29 brand new industry speakers\, as well as returning KOLs including Fernando Martinez\, Naftali Kaminski\, Toby Maher\, and many more\n6 interactive workshops to delve into IPF’s hottest topics\, discuss challenges\, pose your burning questions to leading experts\, and highlight the respiratory pipeline development opportunities including SSc-ILD\, COPD\, and COVID fibrosis\nA brand-new Tissue Repair and Regeneration Day\, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities\nExclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development\n\nGet in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie\, Boehringer Ingelheim\, Bayer\, BMS\, Genentech\, Galecto\, Novartis\, and Trevi Therapeutics. \nFrom navigating pathophysiology and pathobiology\, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research. \nTo know more visit: https://ter.li/6yo2nd
URL:https://www.pharmajournalist.com/event/6th-ipf-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220830
DTEND;VALUE=DATE:20220902
DTSTAMP:20260516T025924
CREATED:20220526T182710Z
LAST-MODIFIED:20220526T182710Z
UID:34236-1661817600-1662076799@www.pharmajournalist.com
SUMMARY:2nd Integrin-Targeted Drug Development Summit
DESCRIPTION:Over the last 12 months\, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma\, Corbus Pharmaceuticals\, Vincerx\, and Morphic are paving the way to develop a safe\, efficacious integrins-targeted drug to modify disease biology\, which will be a game-changer for diseases such as oncology\, autoimmune\, and ophthalmology\, with unmet medical needs. \nIn collaboration with leading integrin drug developers\, including Genentech\, 7 Hills Pharma\, and Pfizer\, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success\, including patient selection biomarkers and dosing. \nGet your critical questions answered to supercharge your clinical programs\, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic\, familiar\, and rare diseases.  \nJoin us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients. \nTo know more visit: https://ter.li/qoq74v
URL:https://www.pharmajournalist.com/event/2nd-integrin-targeted-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260516T025924
CREATED:20220524T085905Z
LAST-MODIFIED:20220524T085905Z
UID:34213-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:Optimizing AAV Safety Summit
DESCRIPTION:Hundreds of clinical trials using AAV are underway\, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline\, the need to administer high doses\, the clinical holds placed on gene therapy trials\, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! \nIn this setting\, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology\, pharmacology\, non-clinical study leads\, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays. \nJoin us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics\, Ask Bio\, Eli Lilly\, Takeda\, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies\, learn how clinical safety signals have changed how companies are approaching their pipeline progression\, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/r92wow
URL:https://www.pharmajournalist.com/event/optimizing-aav-safety-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260516T025924
CREATED:20220713T080736Z
LAST-MODIFIED:20220713T080736Z
UID:34660-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:5th International Cannabinoid-Derived Pharmaceuticals Summit
DESCRIPTION:Over the last half-decade\, we have witnessed game-changing developments within the cannabinoid field\, driving it into a new era of rigorous research\, promising clinical trials and multimillion-dollar deals. Right now\, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3\, pushing for approval to meet the clinical needs of patients with chronic pain\, cancer\, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap\, funding and changing regulation – to name just a few. \nThe 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers\, investors\, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations\, panel discussions and interactive workshops in Boston. \nAgenda highlights include: \n\nPresent a poster of your drug development pipeline at our investor networking session\, and connect with the decision makers looking to fund promising cannabinoid therapeutics\nGet the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor\n(FDA)\nProduce and source high-purity cannabinoids from synthetic\, plant-based and biosynthetic sources with Purisys\, Kinetochem and our other world-leading partners\nHear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria)\, Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)\nStreamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)\nJoin 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals\, and an additional behind-the-scenes workshop on the psychedelics field\, preparing you for exploration into a new area\nConnect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event\n\nThe Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded\, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda
URL:https://www.pharmajournalist.com/event/5th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220917
DTSTAMP:20260516T025924
CREATED:20220516T094442Z
LAST-MODIFIED:20220516T094442Z
UID:34110-1663027200-1663372799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Revolutionizing Genetic Therapy Development & Delivery to the Eye \nDiscovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches \nThe ophthalmology field is bursting with novel genetic approaches for targeting many disorders\, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic\, as well as more innovative outpatient methods such as suprachoroidal delivery\, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders. \nReturning for its 3rd year\, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges\, with focus on discussing and sharing solutions with the key leaders in the industry. \nThis year we have expanded into two streams of learning\, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development. \nGene therapy for ophthalmic disorders has only seen one FDA approved therapy\, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market. \nLeave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments\, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-ophthalmic-disorders/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220916
DTSTAMP:20260516T025924
CREATED:20220620T111850Z
LAST-MODIFIED:20220620T111850Z
UID:34473-1663027200-1663286399@www.pharmajournalist.com
SUMMARY:5th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products \nSkin microbiome research is continuing to gain increasing market traction from a number of stakeholders\, including drug developers and cosmetic brands. For investment and progress to continue\, it is vital to meet and connect with the key opinion leaders in the space. \nNow in its fifth year\, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing\, and product commercialization. \nThis is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics\, drug developers\, cosmeceutical developers\, cosmetic and consumer brands\, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy \nOr become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv \nWe look forward to welcoming you to Boston in September!
URL:https://www.pharmajournalist.com/event/5th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Four Points by Sheraton Boston Logan Airport Revere\, 407 Squire Rd\, Revere\, MA\, 02151\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220924
DTSTAMP:20260516T025924
CREATED:20220317T083147Z
LAST-MODIFIED:20220317T083147Z
UID:33597-1663545600-1663977599@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit
DESCRIPTION:Back to Boston with a bang! With 1\,500 CAR and TCR developers\, 200 speakers\, 150 live presentations\, 20 hours of networking and more surprises in store\, the 7th CAR-TCR Summit will be the BIGGEST ever. \nGain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. \nDiscuss everything from novel allogeneic approaches with enhanced safety considerations\, the latest in vivo gene engineering techniques\, and advances in CMC and analytics to ensure the development of high-quality cell products. \nWith your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms\, learnings from our successes and pitfalls\, and manufacturing automation innovations for large scale consistent production\, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers\, more content and more exclusive insights than ever before! \nTo know more visit: https://ter.li/km5zwy
URL:https://www.pharmajournalist.com/event/7th-car-tcr-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260516T025924
CREATED:20220523T112249Z
LAST-MODIFIED:20220523T112249Z
UID:34202-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:2nd Annual Aseptic Processing Conference
DESCRIPTION:2nd Annual Aseptic Processing Conference  \nConference: 19 – 20 September 2022\nWorkshop: 21 September 2022 \nLondon\, UK\nhttp://www.asepticprocessing.co.uk/PJWL \n \nSponsored by: Dec Group\, Rapid Micro Biosystems\, Raumedic and STERIS\n\nConference Chairman: James Drinkwater\, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance\, F Ziel GMBH \nDriving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles \nSAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference\, this year taking place in London\, on the 19 and 20 September 2022. \nThe Aseptic processing industry has seen consistent growth in recent years\, with advances in innovative therapeutics\, the introduction of novel techniques and personnel protocols\, the integration of robotics and automation in filling lines\, and rise of rapid microbiological methods being just a few of the factors driving this growth. \nThe Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015\, and is projected to exceed 12 billion USD in value by next year\, then to far surpass a total market value of 50 billion USD before the end of the decade. \nJoin us to discuss and address the  Guidance and Regulation including the EU GMP Annex 1\, environmental control delving into the contamination control strategy\, Pharma moving forward 4.0 covering data integrity and data consistency\, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring \nThis event is CPD Accredited  \nEvent Hashtag: #AsepticProcessing  \nBenefits of Attending: \n\nDiscuss the revisions and the impact of Annex 1 on aseptic manufacturing\nExplore the applications of rapid micro methods in the manufacture of sterile products\nDiscover a risk-based approach to cleaning and disinfection\nDelve into case studies of competence in global aseptic manufacturing\nUncover the journey of isolation technology in a large biotech pharmaceutical plant\nAnalyse the new abilities of robotics and automation through their integration into aseptic technique\n\n Who Should Attend? \n\nValidation Managers\nSenior Microbiologists\nSenior QA’s and QC’s\nQuality Control Managers\nHeads of GMP Compliance\nQuality Assurance Experts\nTechnical Operations Leads\nLeaders in Sterility Assurance\nCleanroom Managers\nRegulatory Affairs Managers\nProduction Managers\nQuality Systems Managers\nHeads of Quality Compliance\nProcess Leaders\nSenior Auditors\nBioprocess Research & Development\n\n PLUS – Post-Conference Workshop on 21 September 2022… \nImplementation Strategy of Annex 1 in New or Existing Facilities \nLed by: Richard Denk\, Senior Consultant Aseptic Processing & Containment\, Skan AG \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:https://www.pharmajournalist.com/event/2nd-annual-aseptic-processing-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220921
DTSTAMP:20260516T025924
CREATED:20220524T091925Z
LAST-MODIFIED:20220524T091925Z
UID:34218-1663545600-1663718399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes San Francisco
DESCRIPTION:SAE Media Group’s 3rd Annual Conference\nSeptember 19 – 20\, 2022 | San Francisco\, CA\, USA\n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics\, high concentration\, and large-volume drug products. \n \nThis year’s conference will be assessing the latest developments in new technologies for next generation device design\, including computational simulation approaches forming the digital revolution of devices design. Furthermore\, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices\, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance\, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.  \nOver recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore\, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.  \nAs part of SAE Media Group’s leading injectable drug delivery portfolio\, this event is not to be missed. \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nTo know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco-2022/
LOCATION:Hyatt Centric\, Fisherman’s Wharf\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:richard.jones@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T025924
CREATED:20220519T110535Z
LAST-MODIFIED:20220908T090420Z
UID:34139-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Summit
DESCRIPTION:The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston\, MA this month (September 20 – 22\, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing! \nThis conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data\, allowing you to stay ahead of the curve. \nIf you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription\, purification\, and analytical validation of your mRNA drug substance\, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field. \nMultiple functions from 75+ leading companies and their teams have already registered\, here’s just a snapchat: \n\nDirector – Business Development mRNA Therapeutics\nSenior Director – Manufacturing Science & Technology\nHead of Quality\nPrincipal Applications Scientist – mRNA\nDirector – Formulation and Drug Delivery\nPrincipal Scientist – Early Bioprocess\nSenior Process Development Associate – mRNA\nGroup Leader (RNA Reagents) – Production\nDownstream Scientist – Technical R&D\nScientist II – Analytical Development\nDirector – RNA Therapeutics Development R & D\nDirector – CMC RNA Vaccines Biopharmaceutical Development\nAssociate Director – Drug Substance\nSenior Director – CMC Reg Affairs Regulatory\n\nWith very limited passes remaining\, register today and be part of the conversation. \nTo know more visit: https://ter.li/9v5h9k
URL:https://www.pharmajournalist.com/event/mrna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T025924
CREATED:20220607T100621Z
LAST-MODIFIED:20220607T100621Z
UID:34368-1663632000-1663891199@www.pharmajournalist.com
SUMMARY:2nd NSCLC Drug Development Summit
DESCRIPTION:Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this\, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not\, most will progress and/or develop resistance to currently available treatments. \nNSCLC remains one of the highest tumor indications of unmet clinical need\, with prevalence only set to increase. Focusing from late-line through to early-line\, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC. \nThe 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma\, biotech and academic leaders to address mechanisms of drug resistance\, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication. \nWe will be focusing on: \n\nRefining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting\nInvestigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery\, chemo and/or radiotherapy where applicable\, to define therapeutic options with better safety and efficacy outcomes in second line or beyond\nOvercoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations\nProviding clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients\nIdentifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options\nExploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria\n\nJoin the NSCLC Summit for 3 jam-packed days of presentations\, panel discussions and interactive workshops with over 20 expert industry speakers. \nThere has never been a more important time to rally together to defeat NSCLC and radically change patients lives. \nTo know more visit: https://bit.ly/3mpftud
URL:https://www.pharmajournalist.com/event/2nd-nsclc-drug-development-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220922
DTSTAMP:20260516T025924
CREATED:20220720T075747Z
LAST-MODIFIED:20220720T075747Z
UID:34728-1663632000-1663804799@www.pharmajournalist.com
SUMMARY:Reuters Events: Cell & Gene Therapy USA 2022
DESCRIPTION:Co-create a commercial toolkit that enables suitable\, scalable and sustainable growth.  \nWith over 20 CGTs projected to be approved by 2025\, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth\, unstable infrastructure\, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization. \nTo realize this potential\, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing\, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further\, transforming our healthcare system to guarantee scalable and sustainable growth.     \nDon’t get left behind.   \nJoin us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers\, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization\, readying the world for CGT as a frontline treatment. \nTo know more visit: https://bit.ly/3oepDP3
URL:https://www.pharmajournalist.com/event/reuters-events-cell-gene-therapy-usa-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:daisy.beale@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T025924
CREATED:20220404T083554Z
LAST-MODIFIED:20220404T083554Z
UID:33687-1663718400-1663891199@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference 2022
DESCRIPTION:Part of the 13th annual RNA Therapeutic series of events\nSMi’s 2nd Annual Conference \nOligonucleotide Therapeutics and Delivery Conference 2022\nDate: 21st – 22nd September 2022\nLocation: London\, UK\nWebsite: www.oligonucleotide.co.uk/PharmaJournalist \nAdvancements in extra-hepatic delivery of oligonucleotides \nThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery\, with presentations on targeted delivery mechanisms\, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nListen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials\nDeepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity\nUnderstand the regulatory and CMC environment surrounding oligonucleotide therapeutic development\nExplore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA\nEngage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics\n\nPlus\, two interactive half day pre-conference workshops on 20th September 2022: \n\nOligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench\, Executive Director\, NATA\, Martin Kerr\, Head of Business Development & Partnerships\, Nucleic Acid Therapy Accelerator\, Ritwick Sawakar\, MRC Investigator\, MRC Toxcology Unit\, University Of Cambridge\nManaging CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala\, CEO/Owner/Principal Consultant\, Aurora CMC Consulting \n\nCHAIRS FOR 2022: \n\nEkkehard Leberer\, Senior Life Sciences Consultant\, Elbicon\njimmy Weterings\, Principal Scientist\, AstraZeneca \n\nFEATURED 2022 SPEAKERS INCLUDE:  \n\nShalini Anderson\, Vice President Oligonucleotide Discovery\,AstraZeneca\nHeinrich Haas\, Vice President RNA Formulation & Drug Delivery\, BioNTech\nTamar Grossman\, Global Head of RNA and Targeted Therapeutics\, Janssen pharmaceuticals\nSarahTabrizi\,Director of UCL Huntington’s disease centre\, UCL Institute of Neurology\nMacarena Hernandez-Jimenez\, Chief Scientific Officer\, AptaTargets\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nNick Lench\, Executive Director\, Nucleic Acid Therapy Accelerator\nBart Anderson\,Senior Director of R&D\, Exicure\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nEARLY-BIRD RATES: \n\nBOOK BY 29TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6154 \nE: ngaloria@smi-online.co.uk \nLinkedIn: SMi Pharma \nTwitter: @SMiPharma | #SMiOligonucleotides  \nKeywords: \nSmall interfering RNA\, siRNA\, Antisense therapy\, DNA\, RNA\, nucleic acid\, mRNA\, Micro RNA\, RNA-induced silencing complex\, RISC\, Aptamers\, oligonucleotide\, peptide molecules\, Immunogenicity\, Drug pipeline\, short interfering RNA\, silencing RNA\, RNA interference\, RNAi\, mRNA degradation \nHashtags:  \n#SmallinterferingRNA\, #siRNA\, #Antisensetherapy\, #DNA\, #RNA\, #nucleicacid\, #mRNA\, #MicroRNA\, #RNAinducedsilencingcomplex\, #RISC\, #Aptamers\, #oligonucleotide\, #peptidemolecules\, #Immunogenicity\, #Drugpipeline\, #shortinterferingRNA\, #silencingRNA\, #RNAinterference\, #RNAi\, #mRNAdegradation
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference-2022/
LOCATION:London\, UK
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220929
DTSTAMP:20260516T025924
CREATED:20220531T070301Z
LAST-MODIFIED:20220531T070301Z
UID:34307-1664150400-1664409599@www.pharmajournalist.com
SUMMARY:4th RAS-Targeted Drug Development Summit
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target\, and drugging this high-value oncogene was deemed impossible. Despite this\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is\, in fact\, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation. \nThe 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before\, we will unite 300+ experts to showcase 3-days of exclusive\, never shared before data as we delve into accelerating discovery and emerging strategies\, optimizing translation and pre-clinical development\, and advancing the landscape of clinical trials for combinations and monotherapies. \nWith mounting success in targeted RAS drugs\, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data\, expert insight\, and exclusive discussions with global leaders\, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to advance valuable combination therapies into the clinic\, and finally\, crack resistance to RAS targeted therapeutics. \nAccess the official agenda for more information. \nEarly-bird & team discounts available – Secure your place today.
URL:https://www.pharmajournalist.com/event/4th-ras-targeted-drug-development-summit/
LOCATION:Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR